Medical Sources
Every claim Pureami Tea Company makes is grounded in published, peer-reviewed medical literature. Below are the sources — all available free at PubMed.com.
Our Commitment to Transparency
The three names — Myricetin, DiHydroMyricetin, and Ampelopsin — all refer to the same flavonol. Search any of them on PubMed.com and you will find a substantial body of evidence. Qing Yun Moyeam produces this compound at 30–40% by plant weight, versus 3–6% for ordinary grades.
We do not cherry-pick studies. We have never made a claim not supported by the published literature. All citations below link directly to their source on PubMed or the original journal.
Showing all teas · atherosclerosis-vascular-health. Clear filter
Qing Yun Moyeam
Ampelopsis Grossedentata — Myricetin / DiHydroMyricetin / Ampelopsin
Atherosclerosis / Vascular Health
PubMed
Dihydromyricetin from Moyeam was found to protect blood vessels from the abnormal tissue buildup that contributes to arterial narrowing and heart disease.
PubMed
Dihydromyricetin protected the inner lining of blood vessels from inflammation-induced dysfunction, a key factor in cardiovascular disease.
PubMed
Dihydromyricetin reduced the formation of "foam cells" — the cholesterol-laden cells that build up in arteries and drive atherosclerosis.
PubMed
In an animal model of atherosclerosis, Dihydromyricetin significantly reduced arterial plaque development, demonstrating a direct anti-atherosclerotic effect.
Disclaimer: The research cited above is provided for educational purposes only and reflects the findings of independent researchers. Pureami Tea Company does not claim that Moyeam diagnoses, treats, cures, or prevents any disease. These statements have not been evaluated by the FDA. Consult your healthcare provider before making any changes to your diet or supplement regimen.